Clinical Study Results
ummer?
1. Study Name
Title of the study: A Phase 1 Open-label Study Evaluating the Safety,
Tolerability, Pharmacokinetics and Efficacy of AMG 397 in
Subjects With Selected Relapsed or Refractory
Hematological Malignancies
Brief Title: Safety, Tolerability, Pharmacokinetics and Efficacy of
AMG 397 in Subjects With Multiple Myeloma,
Myelodysplastic Syndrome, and Acute Myeloid Leukemia
Protocol Number: 20170173
NCT Number: NCT03465540
Date of This 11 November 2021
Summary:
What does this summary cover?
This summary shows the main results from one clinical study. The results are only
for this study. Other studies may find different results. Researchers and health
authorities look at the results of many studies to decide which medicines work best
and are safest for patients.
Amgen has committed to make research results available to the public. This
summary has been provided as part of that commitment and should not be used for
any other purpose. It should not be considered to make a claim for any product or to
guide treatment decisions.